These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 7350437)

  • 1. Diazoxide in primary pulmonary hypertension.
    Klinke WP; Gilbert JA
    N Engl J Med; 1980 Jan; 302(2):91-2. PubMed ID: 7350437
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary on studies investigating low-dose diazoxide in hyperinsulinism.
    Huynh T
    Clin Endocrinol (Oxf); 2024 Feb; 100(2):138-139. PubMed ID: 38059616
    [No Abstract]   [Full Text] [Related]  

  • 3. Diazoxide for Neonatal Hyperinsulinemic Hypoglycemia and Pulmonary Hypertension.
    Newman-Lindsay S; Lakshminrusimha S; Sankaran D
    Children (Basel); 2022 Dec; 10(1):. PubMed ID: 36670556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension.
    Redel-Traub G; Sampson KJ; Kass RS; Bohnen MS
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension.
    Le Ribeuz H; Capuano V; Girerd B; Humbert M; Montani D; Antigny F
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32882918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary hypertension occurring with diazoxide use in a preterm infant with hypoglycemia.
    Kylat RI
    Drug Healthc Patient Saf; 2019; 11():7-10. PubMed ID: 30881142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension.
    Bohnen MS; Ma L; Zhu N; Qi H; McClenaghan C; Gonzaga-Jauregui C; Dewey FE; Overton JD; Reid JG; Shuldiner AR; Baras A; Sampson KJ; Bleda M; Hadinnapola C; Haimel M; Bogaard HJ; Church C; Coghlan G; Corris PA; Eyries M; Gibbs JSR; Girerd B; Houweling AC; Humbert M; Guignabert C; Kiely DG; Lawrie A; MacKenzie Ross RV; Martin JM; Montani D; Peacock AJ; Pepke-Zaba J; Soubrier F; Suntharalingam J; Toshner M; Treacy CM; Trembath RC; Vonk Noordegraaf A; Wharton J; Wilkins MR; Wort SJ; Yates K; Gräf S; Morrell NW; Krishnan U; Rosenzweig EB; Shen Y; Nichols CG; Kass RS; Chung WK
    Circ Genom Precis Med; 2018 Oct; 11(10):e002087. PubMed ID: 30354297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.
    Timlin MR; Black AB; Delaney HM; Matos RI; Percival CS
    Pediatr Cardiol; 2017 Aug; 38(6):1247-1250. PubMed ID: 28642988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis.
    Langleben D; Orfanos S
    Pulm Circ; 2017; 7(3):588-597. PubMed ID: 28632001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators.
    Houde C; Bohn DJ; Freedom RM; Rabinovitch M
    Br Heart J; 1993 Nov; 70(5):461-8. PubMed ID: 8260279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary pulmonary hypertension: modern approaches to an old problem.
    Fein S; Frishman W
    Lung; 1980; 158(3):113-9. PubMed ID: 7442300
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of oral diazoxide and minoxidil in refractory hypertension].
    Meier A; Weidmann P; Glück Z; Keusch G; Grimm M; Minder I; Reubi FC
    Klin Wochenschr; 1980 Jul; 58(13):681-7. PubMed ID: 7442081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hazards of diazoxide in pulmonary hypertension.
    Buch J; Wennevold A
    Br Heart J; 1981 Oct; 46(4):401-3. PubMed ID: 7295436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary pulmonary hypertension: effects of nifedipine.
    Dalal JJ; Griffiths BE; Henderson AH
    Br Heart J; 1981 Aug; 46(2):230-1. PubMed ID: 7272141
    [No Abstract]   [Full Text] [Related]  

  • 15. Corticosteroid responsive pulmonary hypertension in systemic lupus erythematosus.
    Pines A; Kaplinsky N; Goldhammer E; Olchovsky D; Frankl O
    Clin Rheumatol; 1982 Dec; 1(4):301-4. PubMed ID: 7188437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detrimental effects of verapamil in patients with primary pulmonary hypertension.
    Packer M; Medina N; Yushak M; Wiener I
    Br Heart J; 1984 Jul; 52(1):106-11. PubMed ID: 6743418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of primary pulmonary hypertension.
    Oakley CM
    Br Heart J; 1985 Jan; 53(1):1-4. PubMed ID: 3966945
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulmonary hypertension.
    Michael JR; Summer WR
    Lung; 1985; 163(2):65-82. PubMed ID: 3927072
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide.
    Chan NS; McLay J; Kenmure AC
    Br Heart J; 1987 Feb; 57(2):207-9. PubMed ID: 3814459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).
    Jones DK; Higenbottam TW; Wallwork J
    Br Heart J; 1987 Mar; 57(3):270-8. PubMed ID: 3552006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.